Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.

Plain-language guide to PMID 20961422 (2010): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 20961422
Journal: BMC clinical pharmacology
Year: 2010
Study type: Randomized Controlled Trial
Authors: Liedert B et al. (5 authors)
DOI: 10.1186/1472-6904-10-14
Registered trial: NCT01034735

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Somatropin is recombinant human growth hormone (GH) used for the treatment of growth failure in children and GH deficiency in adults.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Primary PK endpoints were area under the serum concentration-time curve (AUC0-t) and maximum serum concentration (Cmax).

What Was Measured

Topics PubMed links to this paper include Biological Availability, Drug Tolerance, Drug-Related Side Effects and Adverse Reactions, Freeze Drying, Human Growth Hormone, Recombinant Proteins and Therapeutic Equivalency.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (BMC clinical pharmacology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.